|
|
|
| Expression and Clinical Significance of L1CAM Mel-18 and c-myc in Endometrial Carcinoma |
| ZHANG Jin, et al |
| Liaoning Provincial People's Hospital, Liaoning Shenyang 110000, China |
|
|
|
|
Abstract Objective: To investigate the expression and clinical significance of L1 cell adhesion molecule (L1CAM), melanoma nucleoprotein-18 (Mel-18) and proto oncogene (c-myc) in endometrial carcinoma. Methods: Endometrial carcinoma and paracancer tissue of 80 patients with endometrial cancer in Liaoning Provincial People's hospital from February 2015 to December 2019 were collected for clinical study. The expressions of L1CAM, Mel-18 and c-myc were detected by immunohistochemistry. The relationship between the expression of L1CAM, Mel-18, c-myc and clinicopathological parameters was analyzed. Pearson method was used to analyze the expression correlation of L1CAM, Mel-18 and c-myc. Results: The positive rates of L1CAM, Mel-18 and c-myc in endometrial carcinoma tissues were significantly higher than those in adjacent normal tissues (P<0.005).The expression of L1CAM, Mel-18 and c-myc protein in endometrial carcinoma tissues was correlated with lymph node metastasis and FIGO stage (P<0.05).L1CAM, Mel-18 and c-myc were positively correlated with each other (P<0.05). Conclusion: The positive rates of L1CAM, Mel-18 and c-myc in endometrial carcinoma are increased, and the expression of the three is positively correlated with each other. The expressions of L1CAM, Mel-18 and c-myc were correlated with lymph node metastasis and FIGO stage of endometrial carcinoma.
|
|
|
|
|
|
[1] Lee YC,Lheureux S,Oza AM.Treatment strategies for endometrial cancer: current practice and perspective[J].Curr Opin Obstet Gynecol,2017,29(1):47~58.
[2] Pasanen A,Loukovaara M,Tuomi T,et al. Preoperative risk stratification of endometrial carcinoma:L1CAM as a biomarker[J]. Int Gynecol Cancer,2017,27(7):1318~1324.
[3] Abe S,Yamashita SI,Miyahara SO,et al.Prognostic significance of BMI-1 But not MEL-18 expression in pulmonary squamous cell carcinoma[J].Anticancer Res,2017,37(4):1923~1929.
[4] Buchynska LG,Brieieva OV,Iurchenko NP. Assessment of HER-2/neu,с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas[J]. Exp Oncol,2019,41(2):138~143.
[5] 杨镓宁,邓菲,潘宁.c-Myc调控PIK3R3抑制黑色素瘤B16-F10细胞的迁移和侵袭[J].中国免疫学杂志,2017,33(1):66~71.
[6] Bhatla N,Berek JS,Cuello Fredes M,et al.Revised FIGO staging for carcinoma of the cervix uteri[J].Int Gynaecol Obstet,2019,145(1):129~135.
[7] Powles T,Huddart RA,Elliott T,et al.Phase III,double-Blind,randomized trial that compared maintenance lapatinib versus placebo after frst-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer[J].Clin Oncol,2017,35(1):48~55.
[8] Arend RC,Jones BA,Martinez A,et al.Endometrial cancer: molecular markers and management of advanced stage disease[J].Gynecol Oncol,2018,150(3):569~580.
[9] Giordano M,Cavallaro U. Different shades of L1CAM in the pathophysiology of cancer stem cells[J].Clin Med,2020,9(5):1502.
[10] Versluis M,Plat A,de Bruyn M,et al.L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition[J].Virchows Arch,2018,473(5):591~598.
[11] Lapthanasupkul P,Juengsomjit R,Poomsawat S,et al. Expression profile of polycomb group proteins in odontogenic keratocyst and ameloblastoma[J]. Acta Histochem,2018,120(3):215~220.
[12] Ji H,Cao M,Ren K,et al.Expression and clinicopathological significance of Mel-18 and Bmi-1 in esophageal squamous cell carcinoma[J].Technol Cancer Res Treat,2017,16(6):828~834.
[13] Fallah Y,Brundage J,Allegakoen P,et al. MYC-Driven pathways in breast cancer subtypes[J]. Biomolecules,2017,7(3):53.
[14] Ma S,Lu CC,Yang LY,et al.ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis[J].Exp Clin Cancer Res,2018,37(1):183.
[15] Lancho O,Herranz D. The MYC enhancer-ome:long-range transcriptional regulation of MYC in cancer[J]. Trends Cancer,2018,4(12):810~822. |
|
|
|
2021, Vol. 27 
